REFERENCES
1. Amaral FGD, Cipolla-Neto J. A brief review about melatonin, a pineal hormone. Arch Endocrinol Metab 2018;62:472-9.
2. Tan DX, Manchester LC, Hardeland R, et al. Melatonin: a hormone, a tissue factor, an autocoid, a paracoid, and an antioxidant vitamin. J Pineal Res 2003;34:75-8.
3. Castroviejo D, López LC, Escames G, López A, García JA, Reiter RJ. Melatonin-mitochondria interplay in health and disease. Curr Top Med Chem 2011;11:221-40.
4. Acuña-Castroviejo D, Escames G, Venegas C, et al. Extrapineal melatonin: sources, regulation, and potential functions. Cell Mol Life Sci 2014;71:2997-3025.
5. Majidinia M, Reiter RJ, Shakouri SK, et al. The multiple functions of melatonin in regenerative medicine. Ageing Res Rev 2018;45:33-52.
6. Cipolla-Neto J, Amaral FGD. Melatonin as a hormone: new physiological and clinical insights. Endocr Rev 2018;39:990-1028.
7. Tordjman S, Chokron S, Delorme R, et al. Melatonin: pharmacology, functions and therapeutic benefits. Curr Neuropharmacol 2017;15:434-43.
8. Tan D, Reiter RJ. Mitochondria: the birth place, battle ground and the site of melatonin metabolism in cells. Melatonin Res 2019;2:44-66.
9. Stefulj J, Hörtner M, Ghosh M, et al. Gene expression of the key enzymes of melatonin synthesis in extrapineal tissues of the rat. J Pineal Res 2001;30:243-7.
10. Tan DX, Manchester LC, Qin L, Reiter RJ. Melatonin: a mitochondrial targeting molecule involving mitochondrial protection and dynamics. Int J Mol Sci 2016;17:2124.
11. Reiter RJ, Tan DX, Rosales-Corral S, Galano A, Zhou XJ, Xu B. Mitochondria: central organelles for melatonin's antioxidant and anti-aging actions. Molecules 2018;23:509.
12. Reiter RJ, Sharma R, Pires de Campos Zuccari DA, de Almeida Chuffa LG, Manucha W, Rodriguez C. Melatonin synthesis in and uptake by mitochondria: implications for diseased cells with dysfunctional mitochondria. Future Med Chem 2021;13:335-9.
13. Slominski A, Pisarchik A, Semak I, Sweatman T, Wortsman J. Characterization of the serotoninergic system in the C57BL/6 mouse skin. Eur J Biochem 2003;270:3335-44.
14. Meng X, Li Y, Li S, et al. Dietary sources and bioactivities of melatonin. Nutrients 2017;9:367.
15. Ahmad SB, Ali A, Bilal M, et al. Melatonin and health: insights of melatonin action, biological functions, and associated disorders. Cell Mol Neurobiol 2023;43:2437-58.
16. Kopustinskiene DM, Bernatoniene J. Molecular mechanisms of melatonin-mediated cell protection and signaling in health and disease. Pharmaceutics 2021;13:129.
17. Poza JJ, Pujol M, Ortega-Albás JJ, Romero O. Insomnia Study Group of the Spanish Sleep Society (SES). Melatonin in sleep disorders. Neurologia 2022;37:575-85.
18. Tan DX, Manchester LC, Esteban-Zubero E, Zhou Z, Reiter RJ. Melatonin as a potent and inducible endogenous antioxidant: synthesis and metabolism. Molecules 2015;20:18886-906.
19. Dubocovich ML, Markowska M. Functional MT1 and MT2 melatonin receptors in mammals. Endocrine 2005;27:101-10.
20. Stauch B, Johansson LC, Cherezov V. Structural insights into melatonin receptors. FEBS J 2020;287:1496-510.
21. von Gall C, Stehle JH, Weaver DR. Mammalian melatonin receptors: molecular biology and signal transduction. Cell Tissue Res 2002;309:151-62.
23. Liu J, Clough SJ, Hutchinson AJ, Adamah-Biassi EB, Popovska-Gorevski M, Dubocovich ML. MT1 and MT2 melatonin receptors: a therapeutic perspective. Annu Rev Pharmacol Toxicol 2016;56:361-83.
24. Slominski AT, Kim TK, Slominski RM, et al. Melatonin and its metabolites can serve as agonists on the aryl hydrocarbon receptor and peroxisome proliferator-activated receptor gamma. Int J Mol Sci 2023;24:15496.
25. Slominski AT, Zmijewski MA, Jetten AM. RORα is not a receptor for melatonin. Bioessays 2016;38:1193-4.
26. Vinther AG, Claësson MH. The influence of melatonin on immune system and cancer. Ugeskr Laeger 2015;177:V10140568.
27. Fernández-Lázaro D, Hernández JLG, García AC, del Castillo AC, Hueso MV, Cruz-Hernández JJ. Clinical perspective and translational oncology of liquid biopsy. Diagnostics 2020;10:443.
28. Reiter RJ, Rosales-Corral SA, Tan DX, et al. Melatonin, a Full service anti-cancer agent: inhibition of initiation, progression and metastasis. Int J Mol Sci 2017;18:843.
29. Hill SM, Belancio VP, Dauchy RT, et al. Melatonin: an inhibitor of breast cancer. Endocr Relat Cancer 2015;22:R183-204.
30. Li Y, Li S, Zhou Y, et al. Melatonin for the prevention and treatment of cancer. Oncotarget 2017;8:39896-921.
31. de Almeida Chuffa LG, Carvalho RF, Justulin LA, et al. A meta-analysis of microRNA networks regulated by melatonin in cancer: Portrait of potential candidates for breast cancer treatment. J Pineal Res 2020;69:e12693.
32. Bondy SC, Campbell A. Mechanisms underlying tumor suppressive properties of melatonin. Int J Mol Sci 2018;19:2205.
34. Bhattacharya S, Patel KK, Dehari D, Agrawal AK, Singh S. Melatonin and its ubiquitous anticancer effects. Mol Cell Biochem 2019;462:133-55.
35. Hill SM, Blask DE. Effects of the pineal hormone melatonin on the proliferation and morphological characteristics of human breast cancer cells (MCF-7) in culture. Cancer Res 1988;48:6121-6.
36. Blask DE, Hill SM. Effects of melatonin on cancer: studies on MCF-7 human breast cancer cells in culture. J Neural Transm Suppl 1986;21:433-49.
37. Önder GÖ, Sezer G, Özdamar S, Yay A. Melatonin has an inhibitory effect on MCF-7 and MDA-MB-231 human breast cancer cell lines by inducing autophagy and apoptosis. Fundam Clin Pharmacol 2022;36:1038-56.
38. Liu L, Zhu Y, Xu Y, et al. Melatonin delays cell proliferation by inducing G1 and G2 /M phase arrest in a human osteoblastic cell line hFOB 1.19. J Pineal Res 2011;50:222-31.
39. Gil-Perotin S, Haines JD, Kaur J, et al. Roles of p53 and p27(Kip1) in the regulation of neurogenesis in the murine adult subventricular zone. Eur J Neurosci 2011;34:1040-52.
40. Mediavilla MD, Cos S, Sánchez-Barceló EJ. Melatonin increases p53 and p21WAF1 expression in MCF-7 human breast cancer cells in vitro. Life Sci 1999;65:415-20.
41. Blask DE, Sauer LA, Dauchy RT. Melatonin as a chronobiotic/anticancer agent: cellular, biochemical, and molecular mechanisms of action and their implications for circadian-based cancer therapy. Curr Top Med Chem 2002;2:113-32.
42. Vriend J, Reiter RJ. Breast cancer cells: modulation by melatonin and the ubiquitin-proteasome system - a review. Mol Cell Endocrinol 2015;417:1-9.
43. Rodriguez C, Martín V, Herrera F, et al. Mechanisms involved in the pro-apoptotic effect of melatonin in cancer cells. Int J Mol Sci 2013;14:6597-613.
44. Morsali S, Sabahi Z, Kakaei J, et al. Clinical efficacy and safety of melatonin supplementation in multiple sclerosis: a systematic review. Inflammopharmacology 2023;31:2213-20.
45. Nag S, Qin J, Srivenugopal KS, Wang M, Zhang R. The MDM2-p53 pathway revisited. J Biomed Res 2013;27:254-71.
46. Mediavilla MD, Sanchez-Barcelo EJ, Tan DX, Manchester L, Reiter RJ. Basic mechanisms involved in the anti-cancer effects of melatonin. Curr Med Chem 2010;17:4462-81.
47. Proietti S, Cucina A, Minini M, Bizzarri M. Melatonin, mitochondria, and the cancer cell. Cell Mol Life Sci 2017;74:4015-25.
48. Mortezaee K, Potes Y, Mirtavoos-Mahyari H, et al. Boosting immune system against cancer by melatonin: a mechanistic viewpoint. Life Sci 2019;238:116960.
49. Anisimov VN, Popovich IG, Zabezhinski MA, Anisimov SV, Vesnushkin GM, Vinogradova IA. Melatonin as antioxidant, geroprotector and anticarcinogen. Biochim Biophys Acta 2006;1757:573-89.
50. Gonzalez A, Cos S, Martinez-Campa C, et al. Selective estrogen enzyme modulator actions of melatonin in human breast cancer cells. J Pineal Res 2008;45:86-92.
51. Cos S, González A, Martínez-Campa C, Mediavilla MD, Alonso-González C, Sánchez-Barceló EJ. Estrogen-signaling pathway: a link between breast cancer and melatonin oncostatic actions. Cancer Detect Prev 2006;30:118-28.
52. Menéndez-Menéndez J, Martínez-Campa C. Melatonin: an anti-tumor agent in hormone-dependent cancers. Int J Endocrinol 2018;2018:3271948.
53. del Río B, García Pedrero JM, Martínez-Campa C, Zuazua P, Lazo PS, Ramos S. Melatonin, an endogenous-specific inhibitor of estrogen receptor alpha via calmodulin. J Biol Chem 2004;279:38294-302.
54. Pedrero JM, Del Rio B, Martínez-Campa C, Muramatsu M, Lazo PS, Ramos S. Calmodulin is a selective modulator of estrogen receptors. Mol Endocrinol 2002;16:947-60.
55. Alvarez-García V, González A, Alonso-González C, Martínez-Campa C, Cos S. Melatonin interferes in the desmoplastic reaction in breast cancer by regulating cytokine production. J Pineal Res 2012;52:282-90.
56. Leon-Blanco MM, Guerrero JM, Reiter RJ, Calvo JR, Pozo D. Melatonin inhibits telomerase activity in the MCF-7 tumor cell line both in vivo and in vitro. J Pineal Res 2003;35:204-11.
57. Martínez-Campa CM, Alonso-González C, Mediavilla MD, Cos S, González A, Sanchez-Barcelo EJ. Melatonin down-regulates hTERT expression induced by either natural estrogens (17beta-estradiol) or metalloestrogens (cadmium) in MCF-7 human breast cancer cells. Cancer Lett 2008;268:272-7.
58. Rodríguez-Santana C, Florido J, Martínez-Ruiz L, López-Rodríguez A, Acuña-Castroviejo D, Escames G. Role of melatonin in cancer: effect on clock genes. Int J Mol Sci 2023;24:1919.
59. Alberts B, Johnson A, Lewis J, et al. Cell junctions. In: Molecular biology of the cell. 4th edition. New York: Garland Science; 2002. Available from: https://www.ncbi.nlm.nih.gov/books/NBK26857/ [Last accessed on 2 Apr 2024].
60. Fernández-Lázaro D, García Hernández JL, García AC, Córdova Martínez A, Mielgo-Ayuso J, Cruz-Hernández JJ. Liquid biopsy as novel tool in precision medicine: origins, properties, identification and clinical perspective of cancer's biomarkers. Diagnostics 2020;10:215.
61. Cos S, Fernandez R, Güezmes A, Sánchez-Barceló EJ. Influence of melatonin on invasive and metastatic properties of MCF-7 human breast cancer cells. Cancer Res 1998;58:4383-90.
62. Su SC, Hsieh MJ, Yang WE, Chung WH, Reiter RJ, Yang SF. Cancer metastasis: mechanisms of inhibition by melatonin. J Pineal Res 2017;62:e12370.
63. Goradel NH, Asghari MH, Moloudizargari M, Negahdari B, Haghi-Aminjan H, Abdollahi M. Melatonin as an angiogenesis inhibitor to combat cancer: mechanistic evidence. Toxicol Appl Pharmacol 2017;335:56-63.
64. Reiter RJ, Sharma R, Ma Q, Rorsales-Corral S, de Almeida Chuffa LG. Melatonin inhibits Warburg-dependent cancer by redirecting glucose oxidation to the mitochondria: a mechanistic hypothesis. Cell Mol Life Sci 2020;77:2527-42.
65. Fernández-Lázaro D, Fernández-Lázaro CI, Caballero García A, Córdova Martínez A. [Immunomodulator drugs for the treatment of multiple myeloma]. Rev Med Chil 2018;146:1444-51.
66. Lissoni P, Barni S, Tancini G, et al. Clinical study of melatonin in untreatable advanced cancer patients. Tumori 1987;73:475-80.
68. Kim C, Kim N, Joo H, et al. Modulation by melatonin of the cardiotoxic and antitumor activities of adriamycin. J Cardiovasc Pharmacol 2005;46:200-10.
69. Lissoni P, Barni S, Mandalà M, et al. Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status. Eur J Cancer 1999;35:1688-92.
70. Lissoni P, Chilelli M, Villa S, Cerizza L, Tancini G. Five years survival in metastatic non-small cell lung cancer patients treated with chemotherapy alone or chemotherapy and melatonin: a randomized trial. J Pineal Res 2003;35:12-5.
71. Thomas CR Jr, Reiter RJ, Herman TS. Melatonin: from basic research to cancer treatment clinics. J Clin Oncol 2002;20:2575-601.
72. Mukhopadhyay ND, Khorasanchi A, Pandey S, et al. Melatonin supplementation for cancer-related fatigue in patients with early stage breast cancer receiving radiotherapy: a double-blind placebo-controlled trial. Oncologist 2024;29:e206-12.
73. Berk L, Berkey B, Rich T, et al. Randomized phase II trial of high-dose melatonin and radiation therapy for RPA class 2 patients with brain metastases (RTOG 0119). Int J Radiat Oncol Biol Phys 2007;68:852-7.
74. Del Fabbro E, Dev R, Hui D, Palmer L, Bruera E. Effects of melatonin on appetite and other symptoms in patients with advanced cancer and cachexia: a double-blind placebo-controlled trial. J Clin Oncol 2013;31:1271-6.
75. Kartini D, Taher A, Panigoro SS, et al. Effect of melatonin supplementation in combination with neoadjuvant chemotherapy to miR-210 and CD44 expression and clinical response improvement in locally advanced oral squamous cell carcinoma: a randomized controlled trial. J Egypt Natl Canc Inst 2020;32:12.
76. Lund Rasmussen C, Klee Olsen M, Thit Johnsen A, et al. Effects of melatonin on physical fatigue and other symptoms in patients with advanced cancer receiving palliative care: a double-blind placebo-controlled crossover trial. Cancer 2015;121:3727-36.
77. Palmer ACS, Souza A, Dos Santos VS, et al. The effects of melatonin on the descending pain inhibitory system and neural plasticity markers in breast cancer patients receiving chemotherapy: randomized, double-blinded, placebo-controlled trial. Front Pharmacol 2019;10:1382.
78. Seely D, Legacy M, Auer RC, et al. Adjuvant melatonin for the prevention of recurrence and mortality following lung cancer resection (AMPLCaRe): a randomized placebo controlled clinical trial. EClinicalMedicine 2021;33:100763.
79. Farjallah MA, Hammouda O, Ben Mahmoud L, et al. Melatonin supplementation ameliorates oxidative stress, antioxidant status and physical performances recovery during a soccer training camp. Biol Rhythm Res 2020;51:441-52.
80. Leonardo-Mendonça RC, Ocaña-Wilhelmi J, de Haro T, et al. The benefit of a supplement with the antioxidant melatonin on redox status and muscle damage in resistance-trained athletes. Appl Physiol Nutr Metab 2017; 42:700-7.
81. European Food Safety Authority. Scientific opinion on the supplement of a health claim related to melatonin and reduction of sleep onset latency (ID 1698, 1780, 4080) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. Available from: https://www.efsa.europa.eu/en/efsajournal/pub/2241 [Last accessed on 2 Apr 2024].
82. Spanish Agency for Medicines and Health Products. The Spanish agency for medicines and health products withdraws the food supplement melatonin 3 mg capsules. Available from: https://www.aemps.gob.es/informa/la-aemps-retira-el-complemento-alimenticio-melatonin-3-mg-capsulas/ [Last accessed on 2 Apr 2024].
83. Williams WP 3rd, McLin DE 3rd, Dressman MA, Neubauer DN. Comparative review of approved melatonin agonists for the treatment of circadian rhythm sleep-wake disorders. Pharmacotherapy 2016;36:1028-41.
84. Li X, He J, Li X, Li Y, Zhou Y, Cai S. Neu-P11 - a novel melatonin receptor agonist, could improve the features of type-2 diabetes mellitus in rats. Endokrynol Pol 2021;72:634-42.
85. Zlotos DP, Jockers R, Cecon E, Rivara S, Witt-Enderby PA. MT1 and MT2 melatonin receptors: ligands, models, oligomers, and therapeutic potential. J Med Chem 2014;57:3161-85.
86. Anim-Koranteng C, Shah HE, Bhawnani N, et al. Melatonin-a new prospect in prostate and breast cancer management. Cureus 2021;13:e18124.
87. Gatti G, Lucini V, Dugnani S, et al. Antiproliferative and pro-apoptotic activity of melatonin analogues on melanoma and breast cancer cells. Oncotarget 2017;8:68338-53.
88. Slominski AT, Semak I, Fischer TW, et al. Metabolism of melatonin in the skin: why is it important? Exp Dermatol 2017;26:563-8.
89. Bocheva G, Slominski RM, Janjetovic Z, et al. Protective role of melatonin and its metabolites in skin aging. Int J Mol Sci 2022;23:1238.
